Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Korean Journal of Hepato-Biliary-Pancreatic Surgery ; : 189-197, 2009.
Artículo en Coreano | WPRIM | ID: wpr-140611

RESUMEN

PURPOSE: Cell therapy for various diseases has gained wide acceptance. Because most patients with chronic liver failure have mild-to-severe liver cirrhosis, there are many limitations to clinical applications. We analyzed how to increase cell engraftment in rats with liver fibrosis. METHODS: We used analbuminemic SD rats (NARs) as recipients of syngeneic CAG-EGFP SD hepatocytes obtained by the 2 perfusion method. Hepatic fibrosis was induced with thioacetamide in drinking water for 6 weeks in the recipient NARs. NARs were pre-treated with gadolinium, doxorubicin, and gliotoxin before hepatocyte transplantation. We evaluated the degree of cell engraftment by RT-PCR and immunofluorescent staining for GFP and albumin. The transplanted cells were detected by immunostaining for albumin, and serum albumin was also measured. RESULTS: Although detection of GFP by RT-PCR was variable, albumin was detected in all groups 4 wks after hepatocyte transplantation. GFP and albumin were also detected by immunofluorescent staining 1 and 4 wks after cell transplantation. In control rats, albumin production was maximal at 3 wks, and after that it rapidly decreased. In the gadolinium and doxorubicin-treated group, albumin production was increased up to 4 wks. Albumin production in the gadolinium-treated group was superior to that of the doxorubicin-treated group. CONCLUSION: Kupffer cells play the most important role in cell engraftment in hepatic fibrosis. Therefore, perturbation of kupffer cells in hepatic fibrosis is needed to increase cell engraftment.


Asunto(s)
Animales , Humanos , Ratas , Trasplante de Células , Doxorrubicina , Agua Potable , Enfermedad Hepática en Estado Terminal , Fibrosis , Gadolinio , Gliotoxina , Hepatocitos , Macrófagos del Hígado , Hígado , Cirrosis Hepática , Perfusión , Albúmina Sérica , Tioacetamida , Tratamiento Basado en Trasplante de Células y Tejidos , Trasplantes
2.
Korean Journal of Hepato-Biliary-Pancreatic Surgery ; : 189-197, 2009.
Artículo en Coreano | WPRIM | ID: wpr-140610

RESUMEN

PURPOSE: Cell therapy for various diseases has gained wide acceptance. Because most patients with chronic liver failure have mild-to-severe liver cirrhosis, there are many limitations to clinical applications. We analyzed how to increase cell engraftment in rats with liver fibrosis. METHODS: We used analbuminemic SD rats (NARs) as recipients of syngeneic CAG-EGFP SD hepatocytes obtained by the 2 perfusion method. Hepatic fibrosis was induced with thioacetamide in drinking water for 6 weeks in the recipient NARs. NARs were pre-treated with gadolinium, doxorubicin, and gliotoxin before hepatocyte transplantation. We evaluated the degree of cell engraftment by RT-PCR and immunofluorescent staining for GFP and albumin. The transplanted cells were detected by immunostaining for albumin, and serum albumin was also measured. RESULTS: Although detection of GFP by RT-PCR was variable, albumin was detected in all groups 4 wks after hepatocyte transplantation. GFP and albumin were also detected by immunofluorescent staining 1 and 4 wks after cell transplantation. In control rats, albumin production was maximal at 3 wks, and after that it rapidly decreased. In the gadolinium and doxorubicin-treated group, albumin production was increased up to 4 wks. Albumin production in the gadolinium-treated group was superior to that of the doxorubicin-treated group. CONCLUSION: Kupffer cells play the most important role in cell engraftment in hepatic fibrosis. Therefore, perturbation of kupffer cells in hepatic fibrosis is needed to increase cell engraftment.


Asunto(s)
Animales , Humanos , Ratas , Trasplante de Células , Doxorrubicina , Agua Potable , Enfermedad Hepática en Estado Terminal , Fibrosis , Gadolinio , Gliotoxina , Hepatocitos , Macrófagos del Hígado , Hígado , Cirrosis Hepática , Perfusión , Albúmina Sérica , Tioacetamida , Tratamiento Basado en Trasplante de Células y Tejidos , Trasplantes
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA